

Research Ethics Committee (REC) Reference Number	Integrated Research Application System (IRAS) Number	Name of the Clinical Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Maximum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Target Date To Recruit Patients Agreed?	Date Agreed to Recruit Target Number of Patients	Total Number Of Patients Recruited At The Agreed Target Date	Total Number of Study Participants Recruited	Date That The Trial Closed To Recruitment	Reason For Closure Of Trial	Comments
16/WM/0365	210358	A multi-centre, randomised, double-blind (sponsor unblinded), placebo controlled study with open label extension to investigate the safety and tolerability, pharmacokinetics, pharmacodynamics and efficacy of GSK2982772 in subjects with active ulcerative colitis	Yes	2	2	Date agreed	02/11/2018	1	1	28/01/2019	Recruitment finished	Was due to close 02/11/18 but recruitment was extended to 18/12/18 and then indefinitely until global target achieved. Recruitment finally closed on 28/01/19. Site target of 2 not achieved. 2 consents but one screen failed. Many patients screened but were too ill and needed to be commenced immediately on other meds for their symptoms. By the time the dose was stabilised as per protocol, they didn't fit the inclusion criteria as their disease had improved.
17/NE/0092	220929	CLOVER: A Phase 3, Placebo-Controlled, Randomized, Observer-Blinded Study to Evaluate the Efficacy, Safety and Tolerability of a Clostridium Difficile Vaccine in Adults 50 Years of Age and Older	Yes	17	17	Date agreed	11/01/2019	3	3	14/01/2019	Recruitment finished	Originally no recruitment deadline but substantial amendment 01 formally confirmed as 11/01/19. 3 patients recruited by then with actual close 14/01/19. Issues with recruitment included patients lack of willingness to deal with stool sample decants from diarrhoea episodes, all study visits being above routine care, with only travel/food reimbursed and no inconvenience payments, double contraception methods needed for women of child bearing potential and new drug so reticence to try.